Deregulation of expression and function of cytokines belonging to the transforming growth factor-b (TGF-b) family is often associated with various pathologies. For example, this cytokine family has been considered a promising target for cancer therapy. However, the detailed functions of several cytokines from the TGF-b family that could have a role in cancer progression and therapy remain unclear. One of these molecules is growth/differentiation factor-15 (GDF-15), a divergent member of the TGF-b family. This stress-induced cytokine has been proposed to possess immunomodulatory functions and its high expression is often associated with cancer progression, including prostate cancer (PCa). However, studies clearly demonstrating the mechanisms for signal transduction and functions in cell interaction, cancer progression and therapy are still lacking. New GDF-15 roles have recently been identified for modulating osteoclast differentiation and for therapy for PCa bone metastases. Moreover, GDF-15 is as an abundant cytokine in seminal plasma with immunosuppressive properties. We discuss studies that focus on the regulation of GDF-15 expression and its role in tissue homeostasis, repair and the immune response with an emphasis on the role in PCa development.
INTRODUCTION
Cancer does not merely affect a single cell or an enclosed population of homogenous tumor cells. Thus, studying processes that modulate the tumor microenvironment, particularly the relationship between cancer or stromal cells and the immune system, has immense clinical potential. New findings that describe potential methods to modulate particular cell populations can offer novel strategies for cancer prevention and therapy. Cytokines represent important signaling molecules that regulate the fate of both cancer cells and other cell types within the tumor microenvironment. Several examples exist in clinical practice, where revelation regarding the role of a particular cytokine in cancer progression led to a novel anti-cancer therapy design and significantly improved its efficiency. 1 Deregulation of expression and function of cytokines belonging to transforming growth factor-b (TGF-b) family is often associated with cancer. 2 Thus, cytokines in this family represent potential candidates for drug targeting. However, the detailed cancerrelated functions of several TGF-b family members are still not clear. One of these, growth/differentiation factor-15 (GDF-15), is a divergent member of TGF-b family. 3 This cytokine has been proposed to possess immunomodulatory functions and its high expression is often associated with cancer progression (for review see 4 ). However, studies clearly demonstrating its function in tissue development and hematopoiesis and cancer progression have not been conducted. More detailed elucidation of the physiological function of GDF-15 may lead to innovative new cancer treatment strategies to benefit future patients.
GDF-15 SEQUENCE AND STRUCTURE
GDF-15 (synonyms: macrophage inhibitory cytokine 1, nonsteroidal anti-inflammatory drug (NSAID) activated gene-1, prostate differentiation factor, placental bone morphogenetic protein; placental TGF-b) was discovered simultaneously by several groups 3,5 --8 at the end of 1990s and is localized to chromosome 19 in the region p13.11. Its DNA sequence is 2746 bp long and consists of two exons separated by a single intron. 9 There are at least two GDF-15 alleles, which were identified and characterized in detail by Breit's group. 10 The polymorphism, labeled H6D, consists of a single C-G transversion in exon II at 2423 bp, resulting in a switch from histidine to aspartic acid at codon 202 of the mature protein. This substitution changes the biochemical properties of the mature protein and may alter GDF-15 interactions. The H6D form of GDF-15 has potential clinical relevance, as several studies indicated better prognosis in prostate cancer (PCa) patients carrying the G allele (H6D protein) than those with wild-type GDF-15. 11, 12 According to the Hardy --Weinberg equilibrium, the genotype frequencies in the healthy population were estimated to be 54% for homozygotes containing only histidine (alleles CC), 7% for aspartic acid homozygotes (GG) and 39% for heterozygotes (CG). subsequent proteasomal degradation of the incorrectly folded GDF-15 precursor. 13 The generation of the biologically active form requires removal of the hydrophobic signal sequence followed by disulfide-linked dimerization of GDF-15 monomers and a final cleavage by furin-like protease at the canonic RXXR site (RRAR, position 196) . This process generates the C-terminal form of GDF-15 with a molecular weight of B20 kDa that subsequently enters secretion pathway. 3 Further posttranslational modifications utilize a potential N-glycosylation consensus site at 70 aa (NQS); however, the phosphorylation of mannose residues targeting TGF-b proteins to lysosomes has not been found, 13 suggesting the N-glycosylation of GDF-15 is probably not critical to enter the secretory pathway as in case of TGF-b. 14 The secreted mature protein is a 25-kDa dimer cleaved from the 62-kDa intracellular precursor. 6 The production of biologically active GDF-15 is remarkably complex, and variability in the pool of available GDF-15 forms was suggested to be involved in modulating the tumor microenvironment when differences in GDF-15 expression between malignant and normal tissues were described. The premature proprotein is produced preferentially by cancer cells over normal tissues, and the preprocessed or mature GDF-15 forms have been suggested to be differentially deposited in extracellular matrix (ECM). 15 Current data supports the assertion, that it is the propeptide that mediates interactions of pro-GDF-15 with ECM. 15 Therefore, the tissue availability of GDF-15 depends on ECM degradation, histological composition and architecture or presence of enzymes capable of conversion of pro-GDF-15 to GDF-15, implying a regulation similar to TGF-b. 15, 16 However, direct binding of GDF-15 to latent TGF-b-binding protein-1, which normally sequesters TGF-b and induces binding to the ECM, has not yet been described. Interestingly, GDF-15 stimulates the expression and surface stabilization of matrix metalloproteinases (MT1-MMP) in different cell types, including breast cancer (MCF-7) or human embryonic kidney cells (HEK293) that are sensitive to GDF-15-induced growth arrest. Because GDF-15 is simultaneously a substrate for MT1-MMP, the inhibitory effects on cancer cells are abrogated after MT1-MMP stimulation by GDF-15. This feedback circuit may have particular significance for ECM remodeling in the tumor environment, tissue permeability in metastatic spreading and for tumor growth. 16 The availability of mature GDF-15 or activation of the proprotein by ECM-deposited and microenvironment-regulated proteinases increases the complexity of the GDF-15 regulatory network in a manner tightly linked to the cell and tissue microenvironment, especially under pathological conditions.
GDF-15 IN TISSUE HOMEOSTASIS AND REPAIR
Expression of GDF-15 is tightly associated with conditions of stress or damage in tissues, indicating its role in tissue regeneration or healing, as documented in numerous cases, such as for myocardium. 17 --23 Because GDF-15 is not normally expressed in the healthy heart, it is rapidly upregulated upon stress or with markers of heart damage, such as pressure overload, inflammation, oxidative stress or ischemia, suggesting an anti-apoptotic or protective function during heart failure, arterial hypertension or other cardiovascular insufficiencies. GDF-15 can also offer clinical prognostic information. For example, high-GDF-15 levels in plasma indicate worsened outcomes for particular cardiac malfunctions. 19,20,22 --25 Biological functions of GDF-15 for tissue regeneration in myocardium have not been satisfactorily clarified so far; however, the polymorphonuclear leukocytes 26 or macrophages 27 infiltrating the effected site have been proposed as target populations for GDF-15. The pathological accumulation of polymorphonuclear leukocytes in infarcted myocardium may be prevented by GDF-15 secretion, as it reduces polymorphonuclear leukocyte adhesion by the inhibition of integrin b2 and small GTPase signaling in vitro. 26 Along with outside-in signaling, GDF-15-mediated signal transduction in cardiomyocytes involves the canonical SMAD pathway (SMAD2/3). Both actions not only prevent pathological changes in tissue architecture, such as cardiac hypertrophy and ventricular dilation, but can also inhibit an inappropriate immune response. Under hypoxic conditions in human umbilical vein endothelial cells in vitro, treatment with GDF-15 significantly enhances HIF1a-mediated expression of VEGF and also stabilizes the p53-MDM2 complex leading to ubiquitination and subsequent degradation of p53. 28 Besides cardiovascular tissue, elevated GDF-15 expression has been found in patients with rheumatoid arthritis, 29 congenital anemia 30, 31 and metabolic disorders, such as obesity, diabetes mellitus or preeclampsia. 32, 33 In cases of ineffective hematopoiesis, GDF-15 is likely involved in iron metabolism and erythrocyte differentiation. 34 GDF-15 overexpression was measured after mechanical liver or kidney injury 35 and was capable of inducing the renewal of specific cell populations, including renal acid-secreting collecting duct cells. 36 In mice, GDF-15 may function as a neurotrophic and neuroprotective cytokine, as GDF-15 knock-out mice show postnatal loss of motoneurons in spinal cord and brainstem motor nuclei and dorsal root ganglionic sensory neurons in superior cervical ganglion. 37 In this study, Strelau et al. 37 also demonstrated that GDF-15 produced by Schwann cells promotes the survival of axotomized dopaminergic neurons both in vivo and in vitro. Further investigation in ischemia-induced brain lesions showed strong and rapid induction of GDF --15 mRNA in neurons and partially in microglial cells; however, a comparison of identically lesioned GDF-15-knock-out and wild-type mice did not reveal a significant difference in infarct area, suggesting a role for GDF-15 in post-lesion adaptation and regeneration rather than general protection or neuronal tissue nutrition. 38 In addition to tissue regeneration and repair, GDF-15 is involved in human embryonic development, as it is highly expressed in the placenta during pregnancy, and low levels of GDF-15 in the first weeks of gestation correlate with a higher risk of miscarriage. 39 --41 However, GDF-15 deficient mice do not show abnormalities in the embryonic development and are fully viable and fertile. 37 Soucek et al. 42 measured high levels of GDF-15 in seminal plasma from male donors irrespective of fertility status. Seminal GDF-15 does not appear to influence sperm cell viability or interact with vaginal or cervical cells, but it is capable of inhibiting the proliferation of peripheral blood mononuclear cells in a manner similar to TGF-b-1, but at higher effective concentrations. Moreover, GDF-15-induced the expression of FOXP3 in the CD4 þ CD25 þ peripheral blood mononuclear cells population from healthy donors. 42 Thus, the role of GDF-15 in human reproduction might comprise the meticulous regulation of the immune response during conception, implantation and early embryonic development.
Research showing that GDF-15 is linked to low body weight, nutritional disorders, cancer-associated cachexia and the metabolic response in cancer patients may be critical for clinical practice. 32,43 --45 Similar effects were also observed in experimental animals. 46 Therefore, if GDF-15 contributes to complex stimulatory or inhibitory circuits for the regulation of adipose tissue homeostasis, novel therapeutic approaches for the management of unfavorable disease outcomes or therapeutic side effects may be offered. Johnen et al. 47 showed that GDF-15 can modulate both orexigenic and anorexigenic hypothalamic mediators and therefore indirectly suppress food intake. However, recent results show a direct role for GDF-15, as it was found to be expressed in different adipose tissue depots, and being regulated by, for example, leptin and IL1-b. 48 Expression of GDF-15 is elevated in patients with obesity comorbidities, suggesting a response to cellular stress or tissue damage. 45 Interestingly, Kim et al. 49 demonstrated that breast cancer cell line MDA-MB-231 responses to adipocyte-conditioned medium by dramatic increase of GDF-15 expression, resulting in enhanced invasivity of cancer cells.
The physiological role for GDF-15 in adipose tissue remains largely unknown, and further research in this field in needed. In summary, these findings suggest a role for GDF-15 in the regulation of immune activity, particularly for regulating the inflammatory response and mediating tissue protection or regeneration.
REGULATION OF GDF-15 EXPRESSION
Transcriptional regulation of GDF-15 expression is complex and consists of several independent pathways that depend on tissue, cellular and signaling contexts. GDF-15 is differentially expressed in a variety of adult tissues, especially in reproductive or neural tissue. Moreover, GDF-15 is expressed in extraembryonal tissues, indicating some involvement in embryonic development. 39 --41,50 This complexity in tissue distribution is reflected on the molecular level, implying the utilization of particular transcription machinery or tissue-specific upstream signaling. The GDF-15 promoter sequence is conserved in murine, rat and human tissues and consists of a TATA-like sequence as well as SP1 and AP1/2 consensus sites. 9 The promoter of GDF-15 contains two distinct p53-binding sites with different binding affinity to p53 in vitro. Interestingly, Wong et al. 51 identified a novel p53 transcriptional repressor element in close proximity of the p53-binding sites, suggesting a complex regulation of activation of GDF-15 in a manner dependent on cell or signaling context. GDF-15 represents a typical gene of the adaptive response to cellular stress, as its expression is generally low in quiescent cells, but is rapidly enhanced by different stress stimuli that employ different signaling pathways. Upon stimulation, GDF-15 is strongly expressed in response to NSAIDs and generally results in an antiproliferative phenotype. NSAIDs, used commonly to treat pain and inflammation, inhibit cyclooxygenase-1 and -2 and subsequently activate Egr-1 and p53 transcription factors to induce cellcycle arrest. 52 GDF-15 was shown to be activated by NSAIDs through the p53 pathway 53 and is presumed to be one of the core mediators of NSAID-mediated cell-cycle arrest. However, the effects of NSAIDs on GDF-15 expression are not necessarily mediated by cyclooxygenase inhibition, 54 and other mechanisms have been proposed. GDF-15 expression-mediated cell growth arrest or apoptosis has been induced by various chemicals, particularly NSAIDs, and has often required p53/p21
Cip1/Waf1 activation. 53 More recent studies also demonstrated p53-independent activation of GDF-15, including GSK3b, C/EBP, ATF3 55 or Sp-1/ Egr-1. 56 Lincova et al. 57 separated the mechanisms for GDF-15 induction by NSAIDs and cell growth arrest induced by cyclooxygenase-2 inhibition, suggesting GDF-15 transcriptional regulation independent of cell cycle or lipid signaling. The engagement of GDF-15 in antitumorigenic activities appears to be highly complex, depending on the structure and pharmacokinetic properties of particular NSAID or its metabolites. In APC/ Min mice fed the NSAID sulindac either as a prodrug (DM-sulindac) or a pharmacologically active chemical with antitumor effects (sulindac sulfide), GDF-15 was induced in the liver parenchyma only with sulindac sulfide and not the prodrug. 58 Similarly, GDF-15 expression follows NSAID-induced apoptosis in oral cavity SCC1483 cancer cells, and conditioned medium containing GDF-15 potently inhibits proliferation of these cells. 59 The direct effects of GDF-15-mediated inhibition of cancer cell growth were also described in ovarian cancer cell lines SKOV3 and OVCAR3 that were treated with different NSAIDs. 60 A number of plant-derived organic compounds promising novel anti-tumor effects were shown to induce GDF-15 expression that was preceded by p53 activation (e.g., organosulfuryl structures). 61 Heavy metals, DNA damaging agents, hypoxia or high cell density also stimulate GDF-15 expression in a p53-dependent manner. 62 In addition, particular saponins induce GDF-15 in a PI3K-dependent manner. 63 Further evidence that GDF-15 has a role in cellular stress responses was presented in the work of Schlittenhardt et al., which showed enhanced expression of GDF-15 induced by oxidized low-density lipoproteins, TNFa, certain ceramides or hydrogen peroxide. This group also demonstrated the immunohistochemical colocalization of GDF-15 with PARP, caspase-3, manganese, super-oxide dismutase, cJun and p53 in native atherosclerotic tissue. 64 Taken together, these findings suggest that GDF-15 can be induced by a broad spectrum of cellular or tissue events leading to activation of different intracellular pathways that result in complex phenotypes.
GDF-15 IN CANCER PROGRESSION, SYSTEMIC AND IMMUNE RESPONSE
GDF-15 is generally considered to be part of the cell's antitumorigenic actions, largely because its expression is crucial for the chemopreventive effects of various compounds. 57, 58 However, elevated GDF-15 expression has often been reported during cancer progression, including gastric, ovarian, prostate or breast cancers (see Table 1 ) with various impact on tumors.
4, 65, 66 Despite that the GDF-15 expression profile has been well described in various cancers, its specific role in tumor development remains unclear (Figure 1 ). For example, in breast or gastric cancer, GDF-15 has been shown to be upregulated upon the activation of the MAPK-ERK1/2 or PKB/Akt pathways recruiting the SP-1 family of transcription factors. 67 GDF-15 also induces the phosphorylation and activation of ErbB receptors, mTOR/Akt and ERK1/2 pathways. A potential result of these signal integrations is HIF-1 and VEGF activation. Moreover, inhibition or specific downregulation of ErbB2 also inhibited GDF-15-mediated downstream signaling. 68 These findings indicate the importance of GDF-15 clinically, especially in ErbB2 (HER2)-positive cancers that are sensitive to small molecular inhibitors, such as lapatinib. 69 GDF-15 is strongly upregulated in hepatocellular carcinoma and other liver diseases, such as fibrosis or cirrhosis induced by hepatitis C virus. 70 GDF-15 autocrine signaling of transformed or infected hepatocytes then induces Akt, GSK-3/b catenin, Raf phosphorylation and other downstream targets, such as cell-cycle regulators (cyclins A2, E1 and D2) or adhesion molecules (E-cadherin). Interestingly, impairing GDF-15 can inhibit viral replication. 70 In malignant melanomas, GDF-15 is highly overexpressed, 71 and it is able to mimic VEGF in the neovascularization in the tumor site. 72 Similarly, in malignant glioblastomas, GDF-15 is upregulated as a reaction to anoxia, suggesting more general involvement in vascularization development. 73 Moreover, experimental decrease in GDF-15 expression clearly enhanced natural killer T-cellmediated cytotoxicity, which increased the immunogenicity of glioma cells 74 similar to the effects of TGF-b downregulation. 75 Furthermore, GDF-15 depletion delays the growth of gliomas in mice in vivo. It is likely that GDF-15 acts as a potent suppressor of immune cells while simultaneously enhancing cancer cell growth through autocrine signaling. These observations emphasize the importance of assessing the role of the interactions within the tumor microenvironment for a context-dependent role of GDF-15. Interestingly, two antagonistic in vivo studies were published recently. Senapati et al. 76 demonstrated that ectopic overexpression of GDF-15 led to increased dissemination capacity of PCa cells. However, Zimmers et al. 58 showed that loss of GDF-15 expression abolished the chemopreventive effects of NSAIDs in animal models of hereditary colon cancer.
Thus, the primary effect of GDF-15 on cancer progression can be linked to the regulation of immune responses in the process of tissue regeneration. GDF-15 has been described as a negative regulator of macrophage activation by suppressing the release of TNF-a, IL-1, IL-2 and MCS-F, thus inhibiting the positive feedback of local inflammatory signaling similar to the effects of TGF-b. focus on interactions with regulatory T lymphocytes in a context already defined for TGF-b in various cancers. 42, 77 Taken together, the cancer-associated elevated expression of GDF-15 may have strong predictive potential that could justify the introduction of GDF-15 clinically as a biomarker for particular cancers. Moreover, focusing on its immunosuppressive characteristics, GDF-15 may be specifically targeted to restore the immune-mediated antitumor response.
GDF-15 IN PCA
GDF-15 as a biomarker For PCa, there is a long-term need for both specific and robust markers that would allow precise prediction and estimation of disease outcome. At, present, only PSA was introduced to clinical practice. However, total levels of PSA in serum are not cancer specific, as they are found even in benign diseases, leading to potential false-positive diagnosis of PCa. Improvement was achieved by analyzing alternative molecular forms of PSA, which decreased the number of cancer-negative biopsies in indicated cases. 78 Of particular importance, the measurement of GDF-15 in serum was shown to increase the precision of the information potential of PSA and its forms. The presence of GDF-15 in serum is slightly decreased in BPH or localized PCa compared with normal prostate tissue, 79 but it is elevated in metastatic disease. 80, 81 Interestingly, the inflammatory events in prostate tissue are considered to trigger the transition from normal to benign hyperplasic state and probably reflect an individual's sensitivity to autoimmune lesions. 82, 83 Inflammatory changes of glandular architecture followed by increase of stromal tissue in BPH negatively correlate with GDF-15 expression. 84, 85 Despite the presence of several molecular forms of GDF-15, the analysis of total GDF-15 serum levels showed its clear discriminative capacity for PCa mortality and disease outcome, which justifies further prospective studies to potentially introduce GDF-15 as a clinically important biomarker for PCa. 86 As such, the analysis of overall GDF-15 may offer a robust screening method.
Role of GDF-15 in PCa development Tumor development can be considered either as uncontrolled regeneration or as cellular reprogramming or reversion to the early developmental stages. Thus, lessons from embryonic development can shed light on the complex signaling in organogenesis and tissue formation. In the early development of the normal mouse prostate, GDF-15 is dynamically expressed in dividing epithelium originating from the urogenital sinus and buds, and its expression falls when the stage of developed prostate lobes has been reached. 87 GDF-15 is then reactivated during prostate maturation, and its expression correlates with differentiation markers (e.g., K19). Thus, data from embryonic, fetal and early postnatal murine development suggest a clear dual function for GDF-15 in the regulation of epithelial proliferation in the urogenital sinus as well as its differentiation in the later stages of prostate lobular structure formation. 87 A PCa model based on modified SV-40 region driven by the prostate-specific rat probasin promoter developed by Kasper et al. 88 (CD-1-Tg(Pbsn-Tag) 12T10Rjm, according to the Cancer Model Database) allowed for the detailed study of GDF-15 in the development of prostate intraepithelial neoplasias, which is considered comparable to human prostate intraepithelial neoplasias. Using this model, Noorali et al. 87 showed clear differences in GDF-15 expression among normally developing prostate, prostate hyperplasia and prostate intraepithelial neoplasias. Although the GDF-15 pattern of expression in normal tissue shows two clear peaks (epithelial proliferation in buds and lobes, differentiation of mature prostate), its expression is attenuated in the maturing prostate and is accompanied with a loss of differentiation markers in transgenic tissue showing progression from hyperplasia to prostate intraepithelial neoplasias. Furthermore, GDF-15 expression is strongly upregulated in the tumorigenic state that follows. Moreover, GDF-15 expression is enhanced in developed PCa similar to other cancer types.
Despite that there is low genetic variation in the GDF-15 coding sequence, and existing single nucleotide polymorphisms were not associated with PCa susceptibility, 89 the function of wild-type GDF-15 and its H6D variant can be discriminated in developed PCa. In athymic nude mice inoculated with DU145 PCa cells transfected with appropriate coding sequences, the H6D variant clearly interfered with tumor development by lowering levels of cyclin D1 and IGF-1 in the serum resulting in smaller tumors than in controls with wild-type GDF-15. 90 However, the systemic role for body-weight regulation and the induction of tumor associated cachexia is likely not compromised in the H6D variant compared with wild-type GDF-15, as both proteins significantly reduce the amount of abdominal fat in experimental mice and reduce adipose tissue signaling. 90 A common problem associated with long-term PCa therapy is the development of hormone refractory PCa and resistance to chemotherapy. It is estimated that about 50% of patients treated by first-line castration do not respond to second-line of chemotherapy with Docetaxel. 91 The expression of GDF-15 in PC3 cells with acquired resistance to Docetaxel is increased after chemotherapy exposure compared with parental PC3s. Moreover, a similar trend has been observed in the serum/plasma of patients with Docetaxel-resistant PCa with a clear impact on patients' survival. 92 This correlates well with previously published data; 93 however, in vitro data showed a direct link between GDF-15 and Docetaxel resistance. Androgen independent PCa PC3 cells treated with GDF-15 became partially resistant to Docetaxel and Docetaxel-resistant PC3 cells treated with GDF-15 shRNA showed restored susceptibility to Docetaxel.
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In androgen-sensitive LNCaP cells, GDF-15 is expressed and supports proliferation and clonogenic cell growth. GDF-15 silencing in the LN3 subline of LNCaP cells, which are characterized by a high-metastatic potential, decreased proliferation rate and reduced anchor-independent cell growth on soft agar. 94 In PC3 and DU145 cells, GDF-15 is virtually unexpressed; 95 however, these cells retain sensitivity to GDF-15 under particular conditions. The p53-negative PC3 cells responded to GDF-15 treatment by reducing mobility through matrigel columns. 96 Similarly, for DU145, a slight tumor suppressive effect was reported in vivo.
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To identify a systemic role of GDF-15 in PCa bone metastasis, Wakchoure et al. 46 inoculated athymic nude mice with DU-145 PCa cells overexpressing GDF-15. The histomorphological and X-ray analyses showed enhanced osteoblast differentiation and bone-remodeling activity in sites of bone metastases. This study also showed enhanced osteoclast numbers in metastasis sites; however, using an in vitro macrophage model, another study demonstrated clear inhibitory effects of GDF-15 on osteoclast formation. Under experimental in vitro conditions, GDF-15 inhibited MCSF-RANKL-induced osteoclast differentiation that were derived either from the macrophage cell line RAW264.7 or mononuclear precursors isolated from murine bone marrow. Impaired differentiation resulted in reduced osteoclast numbers in culture and decreased bone resorption. On the molecular level, GDF-15 induced the retention of IkB, an inhibitor of the NFkB transcription factor, in the cytoplasm, thus preventing NFkB-mediated expression of the key transcription factor c-fos and the osteoclast hallmark enzymes cathepsin K and carbonic anhydrase II. 97 Interestingly, GDF-15 is upregulated by vitamin D3 (1,25(OH) 2 D 3 ) in the androgen-dependent PCa cells LNCaP. 98 The GDF-15 protein produced by 1,25(OH) 2 D 3 -stimulated LNCaP cells was the biologically active form that interferes with MCSF-RANKL signaling independently of osteoprotegerin, a physiological regulator of osteoclast differentiation and activity. 97 Further evidences for a role for GDF-15 in cancer spreading and distant metastasis formation were reported by Senapati et al. 76 This in vitro study described enhanced motility and invasion capabilities and changes in the actin cytoskeletal architecture of PC3 and LNCaP cells overexpressing GDF-15. The induction of intracellular signaling by GDF-15 led to the activation of focal adhesion kinases and the small GTPase RhoA, suggesting that GDF-15 moderates direct control over architectural rearrangements and subsequent cell motility. However, using ovarian and prostate SKOV-3 and PC3 cells, respectively, Cheng et al. 96 showed that GDF-15 inhibited cellular migration through matrigel columns through a p53-dependent mechanism. Similarly, GDF-15 has been described as a mediator of NSAIDs-induced inhibition of migration of PCa cells. 99 According to these experimental data, GDF-15 effects may vary depending on signaling status, the genetic background of target cell populations, particularly on the presence of the androgen receptor and/or p53 activity and interaction with immune system (Figure 2 ). Contextual pleiotropy and dual role in cancer, which is general characteristic of TGF-b family cytokines 100 is most likely characteristic also of GDF-15. However, detail mechanisms of its both tumor suppressor and/or promoter action needs to be revealed.
CONCLUSIONS GDF-15 is a distant member of the TGF-b family and is strongly expressed in a great variety of human cancers including PCa; however, its role in cancer pathophysiology remains ambiguous. Nevertheless, the link between GDF-15 expression and the tumor stage or disease outcome is informative, suggesting that GDF-15 may be a clinically relevant biomarker for particular cancers. The physiological role of GDF-15 may involve mediating interactions between different cellular populations and the immune system or enabling mutual regulation in certain microenvironments. Thus, the suppression of certain immune cell populations may be the core systemic mechanism for the role of GDF-15 in cancer development and progression. GDF-15 was first recognized as a factor interfering with macrophage activation. Later studies showed its inhibitory role on the effects of NSAIDs and the suppression of macrophage-derived osteoclasts or regulatory T lymphocytes. The role of GDF-15 in embryonic development remains unresolved. In mice, GDF-15 is not necessary for proper development and knockouts are fully viable and fertile; however, in humans, it likely has a role in feto-maternal interactions and may prevent immune rejection in utero. There is increasing evidence for the involvement of GDF-15 in tissue regeneration or the reaction to different stress conditions. GDF-15-mediated suppressive effects often mimic those observed by generic TGFbs, but there are differences in target population responses. Of particular importance is to clarify the intracellular signals ranging from the receptor formation to the interacting partners that mediate the effects of GDF-15. Increased knowledge of GDF-15-induced signaling pathways in either producing or receptive cells will contribute to the understanding of events that form the complex communication network within the tumor microenvironment. The nature of GDF-15 proteins has two sides, with both tumor-suppressor and oncogenic characteristics. As the cellular, tissue and systemic effects of GDF-15 signaling in well-defined experimental conditions has shown, it is likely that GDF15 is an active and important player in the development of PCa rather than a stress-induced bystander. Therefore, introducing GDF-15 into clinical discussions may offer new possibilities to better understand cancer development and potentially enhance diagnostic or therapeutic strategies. 
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